Literature DB >> 14693766

The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration.

M I Bosscha1, J T van Dissel, E J Kuijper, W Swart, M J Jager.   

Abstract

AIM: To evaluate the clinical efficacy and safety of topical polymyxin B, neomycin, and gramicidin for the treatment of suspected bacterial corneal ulceration at the Leiden University Medical Center.
METHODS: Patients with a diagnosis of a suspected bacterial corneal ulcer between April 1995 and February 2002 were retrospectively identified and reviewed; clinical and microbiological features and response to therapy were analysed. All patients were treated with Polyspectran eye drops.
RESULTS: In total, 91 patients were included in this analysis. Bacteriological cultures of 46 patients (51%) were positive and revealed 51 microorganisms. Staphylococcus aureus (29.4%) and Pseudomonas aeruginosa (23.5%) were the most frequently encountered bacteria. Eighteen patients switched therapy before complete healing of the corneal ulceration, four patients were lost to follow up. Of the 69 patients who completed Polyspectran treatment, re-epithelialisation occurred in 68 patients (99%) and on average took 12.6 (median 8) days. Among 91 patients, there were four perforations and one evisceration. Seven toxic or allergic reactions were reported.
CONCLUSION: This study shows that the combination of polymyxin B, neomycin, and gramicidin is an effective and safe treatment of suspected corneal ulceration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693766      PMCID: PMC1771930          DOI: 10.1136/bjo.88.1.25

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis.

Authors:  A Panda; R Ahuja; S S Sastry
Journal:  Eye (Lond)       Date:  1999-12       Impact factor: 3.775

2.  Strategies for the management of microbial keratitis.

Authors:  B D Allan; J K Dart
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

3.  The role of cultures in the management of ulcerative keratitis.

Authors:  S D McLeod
Journal:  Cornea       Date:  1997-07       Impact factor: 2.651

4.  Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis.

Authors:  N V Prajna; C George; S Selvaraj; K L Lu; P J McDonnell; M Srinivasan
Journal:  Cornea       Date:  2001-03       Impact factor: 2.651

5.  Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group.

Authors: 
Journal:  Ophthalmology       Date:  1997-11       Impact factor: 12.079

Review 6.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.

Authors:  M H Goldstein; R P Kowalski; Y J Gordon
Journal:  Ophthalmology       Date:  1999-07       Impact factor: 12.079

8.  Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers.

Authors:  N Gangopadhyay; M Daniell; L Weih; H R Taylor
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

9.  Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.

Authors:  R A Hyndiuk; R A Eiferman; D R Caldwell; G O Rosenwasser; C I Santos; H R Katz; S S Badrinath; M K Reddy; J P Adenis; V Klauss
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

10.  Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.

Authors:  T P O'Brien; M G Maguire; N E Fink; E Alfonso; P McDonnell
Journal:  Arch Ophthalmol       Date:  1995-10
View more
  4 in total

1.  Bacterial spectrum and resistance patterns in corneal infections at a Tertiary Eye Care Center in South China.

Authors:  Nan Wang; Qiang Huang; Yi-Wei Tan; Li-Ping Lin; Kai-Li Wu
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

2.  Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.

Authors:  Lin Qi; Rongxin Liang; Jingjing Duan; Songze Song; Yunjun Pan; Hui Liu; Mingan Zhu; Lian Li
Journal:  J Antibiot (Tokyo)       Date:  2022-08-23       Impact factor: 3.424

3.  In vitro polymyxin activity against clinical multidrug-resistant fungi.

Authors:  Hanane Yousfi; Stéphane Ranque; Jean-Marc Rolain; Fadi Bittar
Journal:  Antimicrob Resist Infect Control       Date:  2019-04-24       Impact factor: 4.887

Review 4.  Multitarget Approaches against Multiresistant Superbugs.

Authors:  Declan Alan Gray; Michaela Wenzel
Journal:  ACS Infect Dis       Date:  2020-03-19       Impact factor: 5.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.